Published Date: 02 Feb 2024
Compared to abiraterone, enzalutamide causes more weariness, depression, and slower reaction times.
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
Dietary Intervention Shows Promise in Blood Cancers
2.
Using MRD Status to Deescalate Multiple Myeloma Therapy
3.
Minimally invasive prostate cancer treatment shows success in first patient
4.
automated, precise reporting for clonality testing using NGS.
5.
Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap
1.
Breaking Down the Benefits and Risks of Hematopoietic Stem Cell Transplantation
2.
Beyond the Blood: Expanding CAR T-Cell Therapy to Solid Tumors- A New Era of Precision Oncology
3.
Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control
4.
Obesity is a major risk factor for cancer
5.
Integrative Cancer Care: Nutrition, Social Work, Care Coordination, and Genetic Counseling
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation